title: CD24 is a genetic modifier for risk and progression of prostate cancer.
abstract: CD24 plays an oncogenic role in the onset and progression of various human cancers, including prostate cancer. In the present study, we identified two linkage disequilibrium blocks with four recombination hotspot motifs in human CD24 locus. To elucidate whether genetic variants of CD24 are associated with susceptibility to prostate cancer and its disease status, we conducted a case-control association study with two P170 C/T and P-534 A/C polymorphisms of CD24 in 590 patients with prostate cancer and 590 healthy controls. A significant increased risk of prostate cancer was found in men with the P170T/Tgenotype over the P170C/Cgenotype (odd ratio = 1.74, 95% confidence interval = 1.16-2.63, P = 0.008), and in men with the P-534C/Cgenotype over the P-534A/Agenotype (odd ratio = 1.47, 95% CI = 1.18-2.26, P = 0.003). Cochran-Armitage trend analysis showed that the P170Tallele was significantly correlated with an increased risk of prostate cancer progression (P = 0.029, trend between genotypes and stages) and this observation was also validated in an independent sample cohort. Next, we found that tumors with P170Tor P-534Calleles had more twofold increased protein expressions of CD24 as compared to those with P170Cor P-534Aalleles, respectively. Likewise, tumors with a combination of P170T/Tand P-534C/Cgenotypes were associated with a high mRNA level of CD24. Our data suggest a significant association of CD24 genetic variants with prostate cancer onset and progression, which provides new insight into molecular genetics of prostate cancer; however, these findings need to be validated in multiple independent cohorts. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Departmentof Thoracic Surgery, The Second Hospital of Jilin University, Changchun, P.R. China.|Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Yifan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, Second Hospital of Jilin University, Changchun, P.R. China.
authors.forename: Bingjin
authors.initials: B
authors.lastname: Li
authors.affiliation: Departmentof Thoracic Surgery, The Second Hospital of Jilin University, Changchun, P.R. China.|Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, Second Hospital of Jilin University, Changchun, P.R. China.
authors.forename: Xingyi
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Internal Medicine, Section of Medical Oncology, University of Alabama at Birmingham, Birmingham, Alabama.|Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Guru P
authors.initials: GP
authors.lastname: Sonpavde
authors.affiliation: Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Jiao
authors.affiliation: Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Andrea
authors.initials: A
authors.lastname: Zhang
authors.affiliation: Departmentof Thoracic Surgery, The Second Hospital of Jilin University, Changchun, P.R. China.|Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Guangxin
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Department of Pathology, The Second Hospital of Jilin University, Changchun, P.R. China.
authors.forename: Mei
authors.initials: M
authors.lastname: Sun
authors.affiliation: Department of Health and Social Science, Guangdong Medical College, Dongguan, P.R. China.
authors.forename: Chengjing
authors.initials: C
authors.lastname: Chu
authors.affiliation: Anshan Normal University Affiliated Health School, Anshan, P.R. China.
authors.forename: Feng
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.|Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Lizhong
authors.initials: L
authors.lastname: Wang
authors.affiliation: Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, Second Hospital of Jilin University, Changchun, P.R. China.
authors.forename: Ranji
authors.initials: R
authors.lastname: Cui
authors.affiliation: Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.|Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Runhua
authors.initials: R
authors.lastname: Liu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D051927:CD24 Antigen / Q000032:analysis / Q000235:genetics*; D016022:Case-Control Studies; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*
chemical_list: D051927:CD24 Antigen
keywords: CD24; polymorphism; prostate cancer; tumor progression